Back To Search Instructions
Protocols
10 protocols meet the specified criteria
Disease Site: Bladder
Protocol No.TitleStatus
1410518226S1314 A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-invasive Bladder CancerOpen
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
1702242206A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced MalignanciesOpen
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
PHXB-15-0014-10-15A RANDOMIZED PHASE II STUDY OF CO-EXPRESSION EXTRAPOLATION (COXEN) WITH NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED, MUSCLE-INVASIVE BLADDER CANCEROpen
PHXE-16-0204-80-15A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer Open